1. Home
  2. Labeler Index
  3. Proficient Rx Lp
  4. 71205-557
  5. Product Images: Rizatriptan Benzoate

Product Images Rizatriptan Benzoate

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 7 images provide visual information about the product associated with Rizatriptan Benzoate NDC 71205-557 by Proficient Rx Lp, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Figure 1: Estimated Probability of Achieving an Initial Headache Response by 2 Hours in Pooled Studies 1, 2, 3, and 4†† - rizatriptan fig1

Figure 1: Estimated Probability of Achieving an Initial Headache Response by 2 Hours in Pooled Studies 1, 2, 3, and 4†† - rizatriptan fig1

The image depicts a graph showing the estimated probability of achieving a headache response within 2 hours of treatment with rizatriptan benzoate or placebo. The data presented in the graph is obtained by pooling data from four outpatient trials showing evidence of efficacy. The graph shows the Kaplan-Meier plot of the probability over time. Patients who did not achieve a headache response within 2 hours or were taking additional treatment were censored at 2 hours.*

Figure 2: Estimated Probability of Patients Taking a Second Dose of Rizatriptan Benzoate Tablets or Other Medication for Migraines Over the 24 Hours Following the Initial Dose of Study Treatment in Pooled Studies 1, 2, 3, and 4††† - rizatriptan fig2

Figure 2: Estimated Probability of Patients Taking a Second Dose of Rizatriptan Benzoate Tablets or Other Medication for Migraines Over the 24 Hours Following the Initial Dose of Study Treatment in Pooled Studies 1, 2, 3, and 4††† - rizatriptan fig2

Figure 3: Estimated Probability of Achieving an Initial Headache Response with Rizatriptan Benzoate Orally Disintegrating Tablets by 2 Hours in Pooled Studies 5 and 6‡ - rizatriptan fig3

Figure 3: Estimated Probability of Achieving an Initial Headache Response with Rizatriptan Benzoate Orally Disintegrating Tablets by 2 Hours in Pooled Studies 5 and 6‡ - rizatriptan fig3

Figure 4: Estimated Probability of Patients Taking a Second Dose of Rizatriptan Benzoate Orally Disintegrating Tablets or Other Medication for Migraines Over the 24 Hours Following the Initial Dose of Study Treatment in Pooled Studies 5 and 6‡‡ - rizatriptan fig4

Figure 4: Estimated Probability of Patients Taking a Second Dose of Rizatriptan Benzoate Orally Disintegrating Tablets or Other Medication for Migraines Over the 24 Hours Following the Initial Dose of Study Treatment in Pooled Studies 5 and 6‡‡ - rizatriptan fig4

This is a figure depicting the estimated probability of patients taking a second dose of Rizatriptan Benzoate orally disintegrating tablets or other medication for migraines over the 24 hours following the initial dose of study treatment in pooled studies 5 and 6. The plot provides a Kaplan-Mier estimation based on data obtained in 2 placebo-controlled outpatient clinical trials (Studies 3 and 6). Patients not using additional treatments were censored at 24 hours. The plot includes both patients who had a headache response at 2 hours and those who had no response to the initial dose. The figure displays the estimated probability of remedication or rescue over the 24-hour period.*

Figure 5: Observed Percentage of Patients Reporting No Headache Pain by 2 Hours Post-Dose in Study 7 - rizatriptan fig5

Figure 5: Observed Percentage of Patients Reporting No Headache Pain by 2 Hours Post-Dose in Study 7 - rizatriptan fig5

The image shows observed percentage of patients reporting no headache pain by 2 hours post-dose in Study 7, represented graphically. The graph includes two lines: one for Rizatriptan Benzoate OD Tablets and the other for Placebo. The X-axis indicates Hours Post Stage 2 Dose, and the Y-axis shows the percentage of patients (with values ranging from 0% to 100%) reporting no headache pain. There is a key showing that the line with circles represents the placebo and the line with dashes represents Rizatriptan Benzoate OD Tablets.*

71205-557-06 - rizatriptan fig7

71205-557-06 - rizatriptan fig7

This is a medication named Rizatriptan Benzoate ODT 10mg. It is available in a pack of 1X6 orally disintegrating tablets. Each tablet contains 14.53 mg of rizatriptan benzoate, equivalent to 10 mg of rizatriptan. The tablets are white to off-white, circular, biconvex, uncoated with F25' debossed on one side and plain on the other side with a peppermint flavor. It is distributed by Rising Health LLC, Saddle Brook, NJ, and manufactured in India. The medication must be stored at 20°-25°C (68°77°F) and kept out of reach of children. It is relabeled by Proficient Rx LP, Thousand Oaks, CA. Different lots have different SN# MASTER, Exp. 00/00/00, and NDC codes. GTIN: 0037120557065.*

Chemical Structure - rizatriptan str

Chemical Structure - rizatriptan str

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.